Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71788 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 22.04.2026. Verfasst von Debu Tripathy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Piperazines, Pyridines. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc, Pfizer.
Abstract (Originalsprache)
Background
Comorbidities, common in patients with advanced breast cancer (ABC), may impact survival outcomes and health‐related quality of life (HRQoL). Here, we report subgroup analyses on the basis of comorbidities of patients from POLARIS (NCT03280303), a prospective, observational study of patients with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) ABC who were treated with palbociclib plus endocrine therapy in routine clinical practice in North America.
Methods
Real‐world progression‐free survival (rwPFS) and overall survival (OS) were evaluated by line of therapy (1 LOT, ≥ 2 LOT), Charlson Comorbidity Index (CCI) score (0, 1–2, and 3+), and common comorbid disorder categories (cardiovascular, psychiatric, metabolic and nutritional, and blood and lymphatic disorders). HRQoL was assessed using the global health status (GHS)/QoL subscale of the European Organization for Research and Treatment of Cancer Quality‐of‐Life Questionnaire Core 30.
Results
From January 2017 to October 2019, 1250 patients (median age, 64 years) initiated palbociclib‐based therapy. Median rwPFS (95% CI) for patients with CCI scores of 0, 1–2, and 3+ were 20.3 (17.1–24.8), 24.2 (19.4–29.5), and 16.8 (11.2–20.8) months in 1 LOT and 13.7 (6.2–19.7), 13.2 (9.4–17.5), and 14.9 (8.0–21.9) months in ≥ 2 LOT, respectively. Median OS durations (95% CI) were 48.8 (37.3–not estimable [NE]), not reached (43.0–NE), and 34.8 (29.1–44.1) months in 1 LOT and 39.0 (30.6–50.5), 37.9 (26.5–42.6), and 31.6 (20.9–45.2) months in ≥ 2 LOT, respectively. Patients with blood and lymphatic disorders had shorter rwPFS and OS than those with other common comorbidities. GHS/QoL was maintained irrespective of CCI score. Patients with a CCI score of 0 had clinically meaningful and statistically significantly higher mean GHS/QoL scores than patients with a CCI score of 3+ at each assessment.
Conclusions
Patients with HR+/HER2− ABC receiving palbociclib with higher comorbidity burden, especially blood and lymphatic system disorders, had poorer clinical outcomes. GHS/QoL was preserved regardless of comorbidity burden. Trial Registration Clinical trial number: NCT03280303
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, Texas, USA.
- William S. Gibbons Cancer Research Institute, Northwest Georgia Oncology Centers Wellstar, Marietta, Georgia, USA.
- Hematology/Oncology, West Virginia University Cancer Institute, Morgantown, West Virginia, USA.
- Medical Oncology, Cancer Specialists of North Florida, Fleming Island, Florida, USA.
- Oncology & Hematology, Health Partners Institute, Saint Paul, Minnesota, USA.
ORCID-Profile: Debu Tripathy, Meghan S Karuturi, Gabrielle B Rocque
Förderung
- Pfizer Inc
- Pfizer
Zitieren
APA
Tripathy, D., Blum, J. L., Karuturi, M. S., McCune, S., Kurian, S., Moezi, M. M., Anderson, D. M., Ji, Y., Pluard, T. J., Migas, J., Lakhanpal, S., Jepsen, E., Wang, Y., Montelongo, M. Z., Zhang, Z., Cappelleri, J. C., Gauthier, E., & Rocque, G. B. (2026). Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71788
Vancouver
Tripathy D, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi MM, et al. Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71788
BibTeX
@article{Tripathy2026,
author = {Tripathy, Debu and Blum, Joanne L and Karuturi, Meghan S and McCune, Steven and Kurian, Sobha and Moezi, Mehdi M and Anderson, Daniel M and Ji, Yan and Pluard, Timothy J and Migas, John and Lakhanpal, Shailendra and Jepsen, Erin and Wang, Yao and Montelongo, Monica Z and Zhang, Zhe and Cappelleri, Joseph C and Gauthier, Eric and Rocque, Gabrielle B},
title = {Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71788}
}
EUVIMED